BioWorld

March 14, 2005

Savient Terminates Phase II Prosaptide Analgesia Study

Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today) Read More

XOMA Anti-Terrorism Deal Provides Needed Stock Hike

Survival Of Fittest In 2005 For Biotechnology Firms

Raising $7M, ImaRx Plans To Fund Trials, Add Executives

Republicans, Democrats Detail Health Care Agendas For 2005

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...